As of September 30, 2026, Solid Biosciences Inc. carries a market capitalization of 806.54M, placing it among publicly traded companies globally. Its enterprise value stands at 477.24M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 806.54M |
| Enterprise Value | 477.24M |
Solid Biosciences Inc.'s next confirmed earnings release is scheduled for March 16, 2027.
| Earnings Date | 3/16/2027 |
As of September 30, 2026, Solid Biosciences Inc. has 111.56M shares outstanding.
| Shares Outstanding | 111.56M |
These figures are as of September 30, 2026.
| PB Ratio | 2.36 |
| P/TBV Ratio | 2.36 |
| P/FCF Ratio | -4.51 |
| P/OCF Ratio | -4.54 |
As of September 30, 2026, Solid Biosciences Inc. maintains a current ratio of 11.99, meaning it holds 12.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 11.99 |
| Quick Ratio | 11.46 |
| Debt / Equity | 5.74 |
| Debt / EBITDA | -0.09 |
Over the twelve months ended September 30, 2026, Solid Biosciences Inc. posted a negative return on equity (ROE) of -76.87, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -64.86, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 121.00, a quick read on workforce productivity versus industry peers.
| Return on Equity (ROE) | -76.87 |
| Return on Assets (ROA) | -64.86 |
| Employee Count | 121.00 |
As of the close on November 16, 2026, Solid Biosciences Inc.'s stock has gained approximately 52.83% over the past 52 weeks. The 50-day moving average sits at 7.12, while the 200-day moving average is 7.68.
| 52-Week Price Change | 52.83% |
| 50-Day Moving Average | 7.12 |
| 200-Day Moving Average | 7.68 |
Over the twelve months ended September 30, 2026, Solid Biosciences Inc. generated - - in revenue and converted that into -215.27M in net income, yielding earnings per share of -1.72. EBITDA reached -220.08M, while operating income came in at -221.75M.
| Operating Income | -221.75M |
| Pretax Income | -215.27M |
| Net Income | -215.27M |
| EBITDA | -220.08M |
| EBIT | -221.75M |
| Earnings Per Share (EPS) | -1.72 |
As of September 30, 2026, Solid Biosciences Inc. holds 348.93M in cash and equivalents against 19.62M in total debt, resulting in a net debt position of -125.97M. Total book value stands at 342.11M, with working capital of 334.74M providing operational flexibility.
| Cash & Cash Equivalents | 348.93M |
| Total Debt | 19.62M |
| Net Debt | -125.97M |
| Equity (Book Value) | 342.11M |
| Book Value Per Share | 3.07 |
| Working Capital | 334.74M |
Solid Biosciences Inc. produced -198.92M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -1.38M in capital expenditures, free cash flow totaled -200.30M - equivalent to -1.60 per share.
| Operating Cash Flow | -198.92M |
| Capital Expenditures | -1.38M |
| Free Cash Flow | -200.30M |
| FCF Per Share | -1.60 |
These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -22.20: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -38.25, meaning Solid Biosciences Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -38.25 |
| FCF Yield | -22.20 |
Solid Biosciences Inc.'s most recent stock split took place on October 28, 2022 with a 15:1 split ratio.
| Last Split Date | 10/28/2022 |
| Split Ratio | 15:1 |
As of September 30, 2026, Solid Biosciences Inc. has an Altman Z-Score of 5.25, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 5.25 |